导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.65% | 1224/4773 |
| 近一周 | -3.96% | 4941/5465 |
| 近一月 | -1.82% | 1326/5421 |
| 近一季 | -6.66% | 2498/5231 |
| 近半年 | -11.53% | 3742/4920 |
| 近一年 | 23.96% | 358/4394 |
| 近两年 | 83.94% | 798/2954 |
| 近三年 | 61.25% | 460/2253 |
| 成立以来 | 145.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
10.16% 68/4961 |
-4.42% 3505/5312 |
- - |
- - |
| 2025 | 50.14% 468/4813 |
1.16% 1684/3635 |
2.43% 1572/4076 |
29.41% 1224/4524 |
11.97% 148/4813 |
| 2024 | 7.43% 1660/3463 |
10.08% 77/2808 |
-2.20% 1151/3014 |
7.90% 2793/3129 |
-7.52% 2769/3463 |
| 2023 | 0.85% 387/2656 |
6.21% 710/2280 |
-5.22% 1400/2385 |
3.63% 179/2515 |
-3.33% 659/2655 |
| 2022 | -7.39% 143/2207 |
0.11% 115/1919 |
1.92% 1402/2016 |
-5.58% 81/2113 |
-3.86% 1870/2208 |
| 2021 | 39.83% 34/1822 |
1.74% 243/1255 |
12.87% 305/1330 |
29.05% 15/1466 |
-5.64% 1522/1822 |
| 2020 | 16.04% 778/1250 |
-15.44% 981/1028 |
6.60% 859/1067 |
10.15% 581/1164 |
16.87% 146/1184 |
| 2019 | 31.91% 455/1092 |
24.57% 501/754 |
-3.89% 414/804 |
-0.89% 622/850 |
11.17% 76/918 |
| 2018 | -32.97% 543/834 |
- - |
- - |
- - |
-16.38% 635/691 |
| 2017 | 15.66% 245/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.05% 97/605 |
- - |
- - |
- - |
- - |
| 2015 | -4.39% 275/575 |
- - |
- - |
- - |
- - |
| 2014 | 25.75% 182/237 |
- - |
- - |
- - |
- - |
| 2013 | -33.94% 181/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 鹏华资源A VS. 长安沪深300非周期A(740101) |